|
||||||||||||||||||||||
|
|
Phase II Trial of BIBW 2992 in Patients With HER2-Positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Basic Trial Information
Summary The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive metasta tic breast cancer patients after failure of trastuzumab containing regimens. Eligibility Criteria Inclusion Criteria: Inclusion Criteria: 1. Male or female patients with confirmed diagnosis of Stage IIIB or IV HER2-pos itive metastatic breast cancer(HER2 2+ and FISH positive or HER2 3+). 2. Patients must have progressed following receipt of prior standard trastuzumab treatment or standard chemotherapy in conjunction with trastuzumab. Patients wi th visceral disease or rapid progression should not be included if they have not had previous chemotherapy in addition to trastuzumab. Patients who are intolerant to trastuzumab and who have received adequate chemotherapy and/or hormone therapy are eligible upon progression. 3. Age 18 years or older. 4. Life expectancy of at least four (4) months. 5. Written informed consent that is consistent with ICH-GCP guidelines. 6. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance Score 0, 1 or 2. 7. Patients should not have received treatment with chemotherapy or immune therapy within the last 4 weeks (2 weeks for trastuzumab). Patients should not have received treatment with hormone therapy within the last 2 weeks. 8. Patients must have recovered from any therapy-related toxicities from previou s chemo-, hormone-, immuno-, or radiotherapies to CTC less than or equal to Grade 1. 9. Patients must have recovered from previous surgery. 10. Patients must have measurable disease as defined by RECIST criteria. Exclusion Criteria: Exclusion Criteria: 1. Active infectious disease. 2. Gastrointestinal disorders that may interfere with the absorption of the stud y drug or chronic diarrhea. 3. Serious illness or concomitant non-oncological disease considered by the inve stigator to be incompatible with the protocol. 4. Patients with active/symptomatic brain metastases. Patients with a history o f treated brain metastases must have stable or normal MRI scan at screening and be at least three months post-radiation or surgery. 5. Cardiac left ventricular function with resting ejection fraction <50%. 6. Absolute neutrophil count (ANC) less than 1500 cells/mm3. 7. Platelet count less than 100 000 cells/mm3. 8. Bilirubin greater than 1.5 mg/dl (>26 micromol /L, SI unit equivalent). 9. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than three times the upper limit of normal. 10. Serum creatinine greater than 1.5 mg/dl (>132 micromol/L, SI unit equival ent). 11. Women and men (and their partners) who are sexually active and unwilling to use a medically acceptable method of contraception. 12. Pregnancy or breast-feeding. 13. Treatment with other investigational drugs; chemotherapy, immunotherapy, rad iotherapy or hormone therapy (including LHRH agonists, or other hormones taken f or breast cancer), or participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study. Treatment with b isphosphonates is allowed. 14. Prior treatment with an EGFR- or HER2 inhibiting drug (except trastuzumab). 15. Patients unable to comply with the protocol. 16. Active alcohol or drug abuse. 17. Patients with history of other malignancy (except for appropriately treated superficial basal cell skin cancer and surgically cured cervical cancer in situ) unless free of disease for at least 3 years. Trial Lead Organizations/Sponsors Boehringer Ingelheim Pharmaceuticals, Incorporated - Ridgefield
Trial Sites
Link to the current ClinicalTrials.gov record. Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |